Enzyme-linked Immunosorbent Assay for the Diagnosis of Trichomoniasis in Women

Sibau, L; Bebb, Debbie; Proctor, E. M.; Bowie, William

doi:10.1097/00007435-198710000-00008

Cited by 9 publications

(12 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our observed seroprevalence is consistent with findings from the most recent study of Tv infection and PCa (21.4%, using the same seropositivity cut-off point [6]), and our high levels of antibody persistence are consistent with findings from two previous small studies of Tv antibody persistence in predominantly female populations (64–71% persistence over “months to years” in 14 patients [9] and 92% persistence over ≥8 months in 25 patients [10]). They are also consistent with findings from previous studies of other sexually transmitted agents that infect the genital mucosal epithelium and cause curable or non-lifelong infections, such as human papillomavirus and Chlamydia trachomatis (persistence range: 30–83% up to seven years [19–21]; kappa range: 0.79–1.00 over one year [22] and 0.52 over 5–7 years [20]).…”

Section: Discussionsupporting

confidence: 91%

“…Therefore, most epidemiologic studies to date have examined Tv infection in relation to PCa by using serology as a marker of cumulative Tv exposure in older men. Although these studies observed good agreement between blinded replicate specimens (89–94% agreement [5, 6, 8]), only two small older studies, to our knowledge, have examined antibody persistence or intra-individual variability over time [9, 10], both of which were composed mainly of women who tend to be more likely to seroconvert or be seropositive for STIs than men [11–14]. Therefore, we examined Tv antibody persistence and intra-individual variability over time in male participants in the Southern Community Cohort Study (SCCS).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Persistence of Trichomonas vaginalis serostatus in men over time

Sutcliffe¹,

Alderete

Neace

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

Purpose Previous epidemiologic studies have observed positive associations between Trichomonas vaginalis (Tv) serostatus and both prostate cancer (PCa) risk and mortality. However, only a few small older studies have examined Tv antibody persistence over time, all of which were composed mainly of female patients. Therefore, we examined Tv antibody persistence over time, as well as intra-individual variability, among middle- to older-aged men in the Southern Community Cohort Study (SCCS). Methods We tested baseline and repeat plasma specimens (collected 1–3 years later) from 248 male participants for Tv antibodies. We used the same enzyme-linked immunosorbent assay as in previous studies of Tv serostatus and PCa. Results At baseline, 46 (18.5%) participants were seropositive for Tv infection. Seventy-six percent of these men were still seropositive 1–3 years later. A similar proportion of men “seroconverted” (4.0%) as “seroreverted” (4.4%), all of whom had absorbance values near the cut-off point for seropositivity. Overall, substantial agreement was observed between baseline and repeat serostatus (kappa=0.72, 95% confidence interval: 0.60–0.83). Conclusion Tv seropositivity was largely persistent between plasma specimens collected 1–3 years apart from middle- to older-aged men. These high levels of persistence are similar to those observed for other sexually transmitted infections frequently investigated in relation to PCa.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Persistence of Trichomonas vaginalis serostatus in men over time

Sutcliffe¹,

Alderete

Neace

et al. 2015

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Very little is also known about the serologic response to T. vaginalis infection. In studies conducted to date, serum antitrichomonad antibodies have been observed in male and female patients with current trichomonosis (14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27), and in those with a documented history of trichomonosis months to years previously (16,21). Although not specifically investigated for T. vaginalis, the response to other genital, mucosal infections (e.g., Chlamydia trachomatis infection) is frequently stronger in those with chronic rather than acute infections (28).…”

Section: Discussionmentioning

confidence: 99%

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Sutcliffe

Giovannucci

Alderete

et al. 2006

Cancer Epidemiology, Biomarkers &Amp; Prevention

170

217

View full text Add to dashboard Cite

Background: Although several previous case-control studies have investigated associations between sexually transmitted infections (STI) and prostate cancer, most have focused on gonorrhea and syphilis, two well-recognized, symptomatic STIs. Another STI of interest for prostate carcinogenesis is trichomonosis, a less well recognized and frequently asymptomatic STI with known prostate involvement. We investigated this infection in relation to incident prostate cancer in a nested case-control study within the Health Professionals Follow-up Study. Methods: Prostate cancer cases were men diagnosed with prostate cancer between the date of blood draw (1993)(1994)(1995) and 2000 (n = 691). Controls were men who had had at least one prostate-specific antigen test and who were free of prostate cancer and alive at the time of case diagnosis. One control was individually matched to each case by age (n = 691). Serologic evidence of a history of trichomonosis was as-

show abstract

“…The antibody response to T. vaginalis infection is well documented and includes circulating serum and cervicovaginal immunoglobulin A (IgA), IgG, and IgM (8,19,83,113,114,118,119). However, these antibodies appear to provide only limited protection from invading parasites, and antibody titers progressively dwindle after infection is eradicated by treatment (44).…”

Section: Vaccinesmentioning

confidence: 99%

Treatment of Infections Caused by Metronidazole-ResistantTrichomonas vaginalis

et al. 2004

View full text Add to dashboard Cite

Infections with the sexually transmitted protozoan Trichomonas vaginalis are usually treated with metronidazole, a 5-nitroimidazole drug derived from the antibiotic azomycin. Metronidazole treatment is generally efficient in eliminating T. vaginalis infection and has a low risk of serious side effects. However, studies have shown that at least 5% of clinical cases of trichomoniasis are caused by parasites resistant to the drug. The lack of approved alternative therapies for T. vaginalis treatment means that higher and sometimes toxic doses of metronidazole are the only option for patients with resistant disease. Clearly, studies of the treatment and prevention of refractory trichomoniasis are essential. This review describes the mechanisms of metronidazole resistance in T. vaginalis and provides a summary of trichomonicidal and vaccine candidate drugs

show abstract

Enzyme-linked Immunosorbent Assay for the Diagnosis of Trichomoniasis in Women

Cited by 9 publications

References 6 publications

Persistence of Trichomonas vaginalis serostatus in men over time

Persistence of Trichomonas vaginalis serostatus in men over time

Plasma Antibodies against Trichomonas vaginalis and Subsequent Risk of Prostate Cancer

Treatment of Infections Caused by Metronidazole-ResistantTrichomonas vaginalis

Contact Info

Product

Resources

About